GlassScriptPhysician profile
Michael C Cole
NPI 1104515857
$317.44
in general payments reported to CMS, 2019-2025
15 companies · $15.04 in 2025
The $15.04 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.23 · 2024: $221 · 2025: $15.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.11 | 2023-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.97 | 2023-2024 | Xifaxan |
| Erbe USA INC | $25.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.63 | 2024 | Spravato |
| Aimmune Therapeutics, INC. | $19.48 | 2024 | |
| Novo Nordisk INC | $19.28 | 2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $19.18 | 2024 | Breztri |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $16.66 | 2023 | Ztlido |
| Lilly USA, LLC | $16.02 | 2024 | Mounjaro |
| Lundbeck LLC | $15.80 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.20 | 2024 | |
| Hema Biologics, LLC | $15.04 | 2025 | Sevenfact |
| Almatica Pharma LLC | $13.34 | 2024 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.29 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.